Technical Analysis for FTSV - Forty Seven, Inc.

Grade Last Price % Change Price Change
grade A 21.11 -7.94% -1.82
FTSV closed down 7.94 percent on Monday, December 17, 2018, on 2.46 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical FTSV trend table...

Date Alert Name Type % Chg
Dec 17 Slingshot Bullish Bullish Swing Setup 0.00%
Dec 17 Upper Bollinger Band Walk Strength 0.00%
Dec 17 Wide Bands Range Expansion 0.00%
Dec 17 Overbought Stochastic Strength 0.00%
Dec 17 Upper Bollinger Band Touch Strength 0.00%
Dec 14 New 52 Week Closing High Bullish -7.94%
Dec 14 Pocket Pivot Bullish Swing Setup -7.94%
Dec 14 New 52 Week High Strength -7.94%
Dec 14 Upper Bollinger Band Walk Strength -7.94%
Dec 14 Wide Bands Range Expansion -7.94%

Older signals for FTSV ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
Is FTSV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.83
52 Week Low 12.02
Average Volume 100,623
200-Day Moving Average 0.0
50-Day Moving Average 15.0138
20-Day Moving Average 17.604
10-Day Moving Average 19.734
Average True Range 1.7621
ADX 48.91
+DI 32.3393
-DI 9.3117
Chandelier Exit (Long, 3 ATRs ) 18.5437
Chandelier Exit (Short, 3 ATRs ) 17.4863
Upper Bollinger Band 23.4106
Lower Bollinger Band 11.7974
Percent B (%b) 0.8
BandWidth 65.969098
MACD Line 1.9755
MACD Signal Line 1.5661
MACD Histogram 0.4095
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.23
Resistance 3 (R3) 26.50 25.08 25.37
Resistance 2 (R2) 25.08 23.77 24.94 25.09
Resistance 1 (R1) 23.09 22.97 22.38 22.82 24.80
Pivot Point 21.67 21.67 21.31 21.53 21.67
Support 1 (S1) 19.68 20.36 18.97 19.41 17.42
Support 2 (S2) 18.26 19.56 18.12 17.13
Support 3 (S3) 16.27 18.26 16.85
Support 4 (S4) 16.00